Aytu BioPharma (NASDAQ:AYTU – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.24, Zacks reports. The company had revenue of $16.11 million during the quarter, compared to analysts’ expectations of $12.28 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%.
Aytu BioPharma Price Performance
Shares of NASDAQ AYTU traded up $0.10 during midday trading on Tuesday, reaching $2.23. The company’s stock had a trading volume of 246,930 shares, compared to its average volume of 48,834. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The company has a market cap of $23.93 million, a P/E ratio of -0.49 and a beta of 0.26. The business’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $2.33. Aytu BioPharma has a fifty-two week low of $1.65 and a fifty-two week high of $3.07.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on AYTU shares. Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Finally, Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and an average price target of $10.75.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.
Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.
Further Reading
- Five stocks we like better than Aytu BioPharma
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
